Filana Therapeutics Inc Quick Ratio (FLNA) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Filana Therapeutics Inc   (NASDAQ: FLNA)

Filana Therapeutics Inc 's Quick Ratio

FLNA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 2.19 below Filana Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 267 other companies have achieved higher Quick Ratio than Filana Therapeutics Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 0 to 1029.

Explain Quick Ratio?
How much Cash & cash equivalents FLNA´s has?
What are FLNA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FLNA Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 331.33 % 134.31 % -14.33 % -17.84 % -87.84 %
Y / Y Cash & cash equivalent Change -26.21 % -25.72 % -28.79 % -45.79 % -5.51 %
Quick Ratio MRQ 2.19 2.2 2.27 2.58 12.81
FLNA's Total Ranking # 1029 # 0 # # #
Seq. Current Liabilities Change -9.11 % -6.88 % 7.2 % 375.37 % -50.63 %
Seq. Cash & cash equivalent Change -9.35 % -9.97 % -5.61 % -4.22 % -8.75 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 268
Healthcare Sector # 452
Overall Market # 1029


Quick Ratio Statistics
High Average Low
106.49 19.18 1.65
(Mar 31 2021)   (Mar 31 2024)




Financial Statements
Filana Therapeutics Inc 's Current Liabilities $ 40 Millions Visit FLNA's Balance sheet
Filana Therapeutics Inc 's Cash & cash equivalent $ 87 Millions Visit FLNA's Balance sheet
Source of FLNA's Sales Visit FLNA's Sales by Geography


Cumulative Filana Therapeutics Inc 's Quick Ratio

FLNA's Quick Ratio for the trailling 12 Months

FLNA Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 28.11 % -29.06 % -41.73 % -23.93 % 3.84 %
Y / Y Cash & cash equivalent TTM Growth -33.48 % -29.18 % -22.81 % -14.74 % 8.29 %
Quick Ratio TTM 2.31 3.02 3.94 4.03 4.45
Total Ranking TTM # 3845 # 0 # # #
Seq. Current Liabilities TTM Growth 21.25 % 21.13 % -6.21 % -6.99 % -32.86 %
Seq. Cash & cash equivalent TTM Growth -7.13 % -7.12 % -8.46 % -15.76 % -1.12 %

Quick ratio ranking by company, industry and sector >> Back to FLNA Financial Strength Comparisons >> Go to Compare FLNA Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2026 to $39.51 millions, cumulative Quick Ratio decreased to 2.31 below the Filana Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 429 other companies have achieved higher Quick Ratio than Filana Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 0 to 3845.

Explain Quick Ratio?
How much Cash & cash equivalents FLNA´s has?
What are FLNA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 430
Healthcare Sector # 878
Within the Market # 3845


trailing twelve months Quick Ratio Statistics
High Average Low
65.7 18.35 2.23
(Jun 30 2021)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Zentalis Pharmaceuticals Inc   6.01 $ 211.758  Millions$ 35.236  Millions
Camp4 Therapeutics Corporation  5.97 $ 99.209  Millions$ 16.624  Millions
Rocket Pharmaceuticals Inc   5.90 $ 144.379  Millions$ 24.466  Millions
Bridgebio Oncology Therapeutics Inc   5.83 $ 252.275  Millions$ 43.260  Millions
Actinium Pharmaceuticals Inc  5.73 $ 42.132  Millions$ 7.349  Millions
Kura Oncology Inc   5.72 $ 580.823  Millions$ 101.496  Millions
Catalyst Pharmaceuticals Inc   5.71 $ 755.859  Millions$ 132.398  Millions
Cervomed Inc   5.69 $ 12.924  Millions$ 2.272  Millions
Viking Therapeutics Inc   5.67 $ 602.964  Millions$ 106.325  Millions
Kala Bio inc   5.63 $ 8.764  Millions$ 1.557  Millions
Barinthus Biotherapeutics Plc  5.49 $ 65.858  Millions$ 12.001  Millions
Maia Biotechnology Inc   5.44 $ 34.413  Millions$ 6.322  Millions
Arrowhead Pharmaceuticals Inc   5.40 $ 1,595.574  Millions$ 295.220  Millions
Genprex Inc   5.38 $ 18.049  Millions$ 3.354  Millions
Arvinas Inc   5.31 $ 614.900  Millions$ 115.900  Millions
Kiora Pharmaceuticals Inc   5.29 $ 13.872  Millions$ 2.620  Millions
Talphera Inc   5.24 $ 21.108  Millions$ 4.025  Millions
Dogwood Therapeutics inc   5.17 $ 13.228  Millions$ 2.560  Millions
Stablecoin Development Corporation  5.15 $ 18.405  Millions$ 3.576  Millions
Veru Inc   5.12 $ 27.597  Millions$ 5.389  Millions
Chemocentryx Inc.  5.09 $ 0.410  Millions$ 0.081  Millions
Mereo Biopharma Group Plc  4.88 $ 30.487  Millions$ 6.248  Millions
Immunic Inc   4.86 $ 186.629  Millions$ 38.363  Millions
Galera Therapeutics Inc   4.82 $ 5.500  Millions$ 1.141  Millions
Biomea Fusion Inc   4.81 $ 44.693  Millions$ 9.294  Millions
Kalvista Pharmaceuticals Inc   4.69 $ 285.030  Millions$ 60.817  Millions
Oragenics Inc   4.67 $ 6.107  Millions$ 1.308  Millions
Abeona Therapeutics Inc   4.64 $ 168.271  Millions$ 36.290  Millions
Cytokinetics Incorporated  4.59 $ 818.550  Millions$ 178.225  Millions
Edesa Biotech Inc   4.57 $ 10.000  Millions$ 2.188  Millions

Date modified: 2026-09-08T17:42:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.